Bupivacaine HCl
(Synonyms: 盐酸布比卡因) 目录号 : GC12410
An Analytical Reference Standard
Cas No.:18010-40-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
| Cell experiment [1]: | |
|
Cell lines |
FDB muscle fibers |
|
Preparation method |
The solubility of this compound in DMSO is > 10.3 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
1 mM; 40 mins |
|
Applications |
In FDB muscle fibers treated with 1 mM Bupivacaine HCl for 40 mins, the TMRM signal was substantially lost and the fiber shortened significantly. The TMRM signal decreased within about 30 mins, and depolarization was inhibited by CsA, which indicated that Bupivacaine facilitated the opening of the permeability transition pore, eventually causing mitochondrial depolarization. |
| Animal experiment [2]: | |
|
Animal models |
ACLT osteoarthritic rats |
|
Dosage form |
0.5%, 10 mL; intra-articular injection; once a week for 5 consecutive weeks |
|
Applications |
In ACLT osteoarthritic rats treated with Bupivacaine HCl, the relative weight-bearing values were significantly lower at the 6th and 7th weeks. Besides, Bupivacaine HCl did not show any significant effect on the viability and density of chondrocytes, as well as the histological characteristics of articular cartilage when compared with saline solution injections. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Irwin W, Fontaine E, Agnolucci L, Penzo D, Betto R, Bortolotto S, Reggiani C, Salviati G, Bernardi P. Bupivacaine myotoxicity is mediated by mitochondria. J Biol Chem. 2002 Apr 5;277(14):12221-7. [2]. Iwasaki K, Sudo H, Kasahara Y, Yamada K, Ohnishi T, Tsujimoto T, Iwasaki N. Effects of Multiple Intra-articular Injections of 0.5% Bupivacaine on Normal and Osteoarthritic Joints in Rats. Arthroscopy. 2016 Oct;32(10):2026-2036. |
|
| Cas No. | 18010-40-7 | SDF | |
| 别名 | 盐酸布比卡因 | ||
| 化学名 | 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide;hydrochloride | ||
| Canonical SMILES | CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl | ||
| 分子式 | C18H28N2O.HCl | 分子量 | 324.89 |
| 溶解度 | ≥ 10.25mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.078 mL | 15.3898 mL | 30.7796 mL |
| 5 mM | 0.6156 mL | 3.078 mL | 6.1559 mL |
| 10 mM | 0.3078 mL | 1.539 mL | 3.078 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet